Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Nailbiter2on Jan 20, 2024 4:06pm
305 Views
Post# 35837518

Global surge in cancer cases among under-50s

Global surge in cancer cases among under-50s

Global cancer cases in people under the age of 50 have risen by 79 per cent between 1990 and 2019, according to new research.

Cancer deaths in the same age group also grew by more than 27 per cent, with more than 1 million under-50s a year now dying of cancer.

Cancers of the breast, windpipe, lung, bowel and stomach are responsible for the biggest death toll.

The University of Edinburgh-led team looked at the impact of 29 cancers on people aged between 14 and 49 years-old in more than 200 countries and regions.

Their analysis found that cancer cases worldwide rose from 1.82 million in 1990 to 3.26 million in 2019.

Breast cancer accounted for the largest number of cases – 13.7 per every 100,000 people. 

The fastest rise was seen in windpipe and prostate cancers, growing 2.38 per cent and 2.23 per cent per year respectively.

The highest rates of early onset cancers in 2019 were seen in North America, Australasia, and Western Europe.

Upward trend

Based on the trends for the past three decades, researchers estimate that the global number of new early onset cancer cases and associated deaths will rise by a further 31 per cent and 21 per cent, respectively, in 2030, with those in their 40s the most at risk. 

Global surge in cancer cases among under-50s | The University of Edinburgh

Comment on this Post

<< Previous
Bullboard Posts
Next >>